SCYNEXIS, Inc. (SCYX)
NASDAQ: SCYX · Real-Time Price · USD
0.8903
-0.0017 (-0.19%)
At close: Mar 12, 2026, 4:00 PM EDT
0.8502
-0.0401 (-4.50%)
After-hours: Mar 12, 2026, 7:02 PM EDT
SCYNEXIS Employees
SCYNEXIS had 18 employees as of December 31, 2025. The number of employees decreased by 10 or -35.71% compared to the previous year.
Employees
18
Change (1Y)
-10
Growth (1Y)
-35.71%
Revenue / Employee
$735,750
Profits / Employee
-$307,464
Market Cap
39.76M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 18 | -10 | -35.71% |
| Dec 31, 2024 | 28 | -1 | -3.45% |
| Dec 31, 2023 | 29 | -7 | -19.44% |
| Dec 31, 2022 | 36 | -20 | -35.71% |
| Dec 31, 2021 | 56 | 18 | 47.37% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| InterCure | 320 |
| Zhengye Biotechnology Holding | 277 |
| Rockwell Medical | 244 |
| Cumberland Pharmaceuticals | 91 |
| Aytu BioPharma | 83 |
| Assertio Holdings | 58 |
| BioXcel Therapeutics | 37 |
| Talphera | 13 |
SCYX News
- 8 days ago - SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 14 days ago - SCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247 - GlobeNewsWire
- 23 days ago - CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors - GlobeNewsWire
- 2 months ago - SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement - GlobeNewsWire
- 4 months ago - SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSK - GlobeNewsWire
- 4 months ago - SCYNEXIS Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 5 months ago - SCYNEXIS and GSK Resolve Their Disagreement Related to the Restart of the Phase 3 MARIO Study - GlobeNewsWire
- 6 months ago - SCYNEXIS Announces Multiple Presentations Highlighting Data from its Second-Generation Fungerp, SCY-247, at the 12th Congress on Trends in Medical Mycology (TIMM-12) - GlobeNewsWire